Oncología Traslacional
ONCTRAS
Medical University of Vienna
Viena, AustriaPublicacións en colaboración con investigadores/as de Medical University of Vienna (15)
2024
-
Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma
Journal of Personalized Medicine, Vol. 14, Núm. 2
-
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284
2023
-
ESGO/ESTRO quality indicators for radiation therapy of cervical cancer
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 183, pp. 109589
-
ESGO/ESTRO quality indicators for radiation therapy of cervical cancer
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 862-875
-
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles
Cell Reports Medicine, Vol. 4, Núm. 12
-
Prognostic factors in patients with uterine sarcoma: The SARCUT study
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 897-904
2022
-
There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer
International Journal of Gynecological Cancer
2021
-
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Radiotherapy and Oncology, Vol. 154, pp. 327-353
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39
2019
-
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428
2018
-
Safety and dose modification for patients receiving niraparib
Annals of Oncology, Vol. 29, Núm. 8, pp. 1784-1792
2016
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052
-
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): A randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICOENGOT- GCIG intergroup study (HECTOR)
Annals of Oncology, Vol. 27, Núm. 12, pp. 2236-2241
2013
-
Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
Clinical Breast Cancer, Vol. 13, Núm. 6, pp. 421-432.e8